Theraclone Sciences
Theraclone Sciences is a Seattle-based private biotech founded in 2004 that develops novel therapeutic antibodies targeting infectious diseases and inflammation, having raised approximately $63 million in venture financing between 2004 and 2015.
- Company typePrivate
- Founded2004
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Theraclone Sciences firmographics
Firmographics- Name
- Theraclone Sciences
- Website
- https://theraclone-sciences.com
- Company type
- Private
- Founded year
- 2004
- Headcount range
- 11–50 employees
- Short description
- Theraclone Sciences is a Seattle-based private biotech founded in 2004 that develops novel therapeutic antibodies targeting infectious diseases and inflammation, having raised approximately $63 million in venture financing between 2004 and 2015.
- Ownership category
- akta.pro rank
Theraclone Sciences industry classification
Industry- Product category
- Therapeutic Antibody Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Theraclone Sciences is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Markets served
Theraclone Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Theraclone Sciences product offering
Product offeringCore offering
Theraclone Sciences is a Seattle-based biotechnology company that discovers and develops novel therapeutic monoclonal antibodies targeting infectious diseases, inflammation, and oncology. The company leverages its proprietary I-STAR antibody discovery platform to identify and engineer fully human antibodies for clinical development, advancing candidates from preclinical through Phase I/II clinical stages.
Differentiator
Problem solved
Functional benefit
Products and services
- Infectious disease antibody pipeline Therapeutic monoclonal antibody candidates targeting infectious disease pathogens, intended for out-licensing or co-development with pharmaceutical partners.
- Inflammation antibody pipeline Therapeutic monoclonal antibody candidates targeting inflammatory disease pathways for licensing to pharmaceutical partners.
- Oncology antibody pipeline Therapeutic monoclonal antibody candidates targeting oncology-related antigens for out-licensing to pharma partners.
- I-STAR antibody discovery platform Proprietary antibody discovery technology platform that identifies and isolates fully human monoclonal antibodies for therapeutic development in infectious disease, inflammation, and oncology.
Companies that use Theraclone Sciences
Customer profileIdeal customer profiles1 record
Theraclone Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Theraclone Sciences competitors and assessment
Company assessmentDirect peers
- Vir Biotechnology: Clinical-stage antibody developer focused on infectious diseases including RSV, influenza, and hepatitis; directly comparable to Theraclone in target indications and antibody modality.
- Aridis Pharmaceuticals: Develops monoclonal antibodies for infectious diseases, particularly hospital-acquired pneumonia; comparable in indication focus, modality, and small-cap biotech profile.
- Adimab: Antibody discovery platform with partnerships across infectious disease and inflammation; comparable platform-based business model leveraging antibody engineering.
- Atreca: Clinical-stage antibody developer leveraging immune-repertoire analysis to discover therapeutics in oncology and infectious disease; similar biotech-stage profile to Theraclone.
Broad incumbents
- Regeneron Pharmaceuticals: Large-cap antibody leader (Dupixent, Inmazeb) with inflammation and infectious disease franchises; sets the competitive benchmark Theraclone would need to differentiate against.
- Emergent BioSolutions: Specialty biopharmaceutical company focused on infectious disease therapeutics and vaccines; comparable commercial-stage peer in the same indication space.
- Genentech (Roche): Pioneer in monoclonal antibody therapeutics (Actemra, Ocrevus) including inflammation and infectious disease; broad incumbent against which Theraclone's pipeline must compete.
Emerging players
- AbCellera Biologics: Antibody discovery and engineering platform with multiple infectious-disease partnerships; comparable technology-driven antibody platform with broader pipeline reach.
- MacroGenics: Clinical-stage developer of antibody-based therapeutics including bispecifics for inflammatory and autoimmune diseases; comparable therapeutic-area focus and modality.
- Visterra: Clinical-stage antibody company focused on infectious diseases and inflammation; acquired by Otsuka, illustrating a relevant exit pathway for a peer-profile antibody company.
Market position
Customer concentration
Theraclone Sciences social profiles
Digital presenceTheraclone Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Theraclone Sciences leadership team
Management profileNumber of profiles
Theraclone Sciences funding detail
Funding detailFunding overview
Funding rounds8 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Theraclone Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Theraclone Sciences
What does Theraclone Sciences do?
Theraclone Sciences is a Seattle-based biotechnology company that discovers and develops novel therapeutic monoclonal antibodies targeting infectious diseases, inflammation, and oncology. The company leverages its proprietary I-STAR antibody discovery platform to identify and engineer fully human antibodies for clinical development, advancing candidates from preclinical through Phase I/II clinical stages.
When was Theraclone Sciences founded?
Theraclone Sciences was founded in 2004. It employs 11 to 50 people.
Where is Theraclone Sciences based?
Theraclone Sciences is headquartered in Seattle, United States, in the North America region.
Who are Theraclone Sciences's main competitors?
Direct peers on record are Vir Biotechnology, Aridis Pharmaceuticals, Adimab and Atreca. Broad incumbents are Regeneron Pharmaceuticals, Emergent BioSolutions and Genentech (Roche). Emerging players are AbCellera Biologics, MacroGenics and Visterra.
Does Theraclone Sciences have an API?
No public API is recorded for Theraclone Sciences.
What industry is Theraclone Sciences in?
Theraclone Sciences's product category is Therapeutic Antibody Discovery. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.